The objective of the study is to evaluate the impact of the new highly active antiretroviral biotechnology medicines (tenofovir disoproxil, emtricitabin and darunavir) 
Introduction
the advancement in AiDS therapy with the discovery of lots of new biotechnology medicines moves it from being a fatal condition to a chronic but disabling illness (10) . the antiretroviral therapy for people living with hiV/AiDS is an important part of their health care that allows them to live in the community as long as possible while meeting a variety of acute and chronic care needs (2, 17) .
the cost of the new biotechnology products addresses a subset of challenges for policymakers and planners that are critical to achieving universal access to comprehensive hiV prevention, treatment and care (8) . these issues were posed in the 2006 'Making the money work' the Joint United nations Programme on hiV/AiDS (UnAiDS) Annual Report (26) . Proposed measures include the successful mobilization of financial resources to sustain the rapid expansion of prevention, treatment and care programmes, the strategic placement of labour, capital and financial resources needed to scale up programmes, and the efficient implementation of alternative strategies identified by sound and practical research methodology to achieve the maximum positive impact on hiVinfected populations.
Budget impact analysis is a new research methodology that focuses upon controlling the total financial impact of introducing a new technology within the health care budget (20) . Budget impact models are useful tools for health care managers to make appropriate decisions about the patients' treatment and budget allocation (19) . however, with the increasing number of new, high-cost biotechnologies and the decreasing availability of healthcare resources, the risk has grown (25) . every new medicine requires careful evaluation of the impact on health care budget in the attempt to cover as many patients as possible within the scarce resources (3, 11, 12) .
Bulgaria is a country with low hiV prevalence in the general population but there is a risk of rapid spread of epidemics in a separate group, defined as "most-at-risk". For these groups there is already epidemiological evidence and the main concern is the possibility of transmission of the infection to the general the therapy is consistent with the clinical characteristics of every patient, the stage of the disease, the viral load and the number of cD4+ cells (7, 9, 27) . As part of the centralized european procedure all of the antiretroviral medicines are authorized for sale in Bulgaria which makes them available for the therapy of AiDS patients (lamivudine, zidovudine, abacavir, lopinavir, ritonavir, efavirenz, etc.) (1, 23) . Recently the newest antiretroviral drugs like tenofovir disoproxil, emtricitabine and darunavir have been authorized (28) .
BUDGET IMPACT MODEL OF NEW ANTIRETROVIRAL BIOTECHNOLOGY MEDICINES FOR TREATMENT OF HIV/AIDS PATIENTS IN BULGARIA
the diagnosis, control and treatment of every registered patient are paid by the republic budget. thus, the budget impact analysis is important to evaluate the influence of new biotechnology medicines on the healthcare system and to help calculate the health budget for AiDS management in the beginning of each year (4, 5, 24) .
the objective of the study is to evaluate the impact of the new highly active antiretroviral biotechnology medicines (tenofovir disoproxil, emtricitabine and darunavir) on the clinical centre health care budget for AiDS in 2011. the point of view is that of clinical centre and the time horizon is one year.
Materials and Methods
the Budget impact model is created according to the international guidelines following the approach as described in Table 1 (19) .
Budget impact of the new biotechnology medicines is calculated as a difference among:
Cost of illness new practice -Cost of illness current practice . this calculation is repeated for every particular dosage regimens.
the costs per patient included in the model are calculated using the following formulas:
1) Mean annual medicines cost=the therapeutic regime cost per day × 365;
2) Total annual medicines cost=Mean annual medicines cost × number of patients on the particular regimen;
3) Total cost of additional resources=number of patients on the treatment regimen × cost of the physician consultations and laboratory tests × number of months. the computer simulation model was created for the Bi analysis at the exchange rate 1 euro=1.95 BGn.
the observed population is from the biggest one of the three clinical centres in Bulgaria for diagnosis, control and treatment of hiV/AiDS patients -the University Specialized hospital for Active and intensive care of infectious and Parasite Diseases.
the resources, included in the model are the medicines, physician's consultation, follow up of the patients, hospitalization, clinical and paraclinical monitoring, viral load monitoring with their respective costs ( Table 2) .
two scenarios have been considered depending on the line of therapy-i st and ii nd line of therapy. the information about the treatment algorithms was gathered from the university clinic on the basis of the analysis of patient records for the current state therapy and expert opinion about the new state therapy. it was also revised and the international guidelines AZT-LPV/r-ENF-TDF 2186.91 1 Abbreviation of medicines in the therapeutic regimes TDF-tenofovir disoproxil fumarate; FTC-emtricitabine; DRV-darunavir; EFV-efavirenz; ddI-didanosine; SQV-saquinavir; r-ritonavir; AZT-zidovudine; d4T-stavudine; ABC-abacavir; ATV-atazanavir; ENF-enfuvirtide; ETV-etravirine; LPV/rlopinavir/ritonavir; 3tc-lamivudine on antiretroviral therapy and compared with the established practice and expert opinion.
Results and Discussion
Treatment algorithms for HIV infected patients Antiretroviral therapy aims to reduce the morbidity and mortality related to hiV infection, to restore and enforce the immune system, to suppress the viral load durably and to the highest degree, to prevent hiV transmission and last but not least to improve the quality of life of the people living with hiV-infection (23, 27 
recommended). the antiretroviral therapy is usually a combination of nucleoside inhibitors (nRtiS), nonnucleoside reverse transcriptase inhibitors (nnRtiS) and protease inhibitors (Pi)
. those combinations are known as highly active antiretroviral therapies and all medicines included in the combinations are biotechnology products. tenofovir disoproxil and emtricitabine are nRtiS, and darunavir is a Pi. the analysis of the patient records and expert opinion revealed that the current therapeutic practice in the clinic follows the international guidelines. the majority of the patients receiving antiretroviral therapy with the newly registered medicines are treatment-naive and start this therapy for the first time. Only a few have been switched to antiretroviral combination with the new medicines when their clinical indicators did not match the requirements of the guidelines and are progressively worsening.
Budget impact calculation
According to the patients' records analysis in the current state on i st line therapy are 140 patients and on ii nd line therapy are 2. their monthly cost per patient is presented on Table 3 . the cohort of new patients using the biotechnology medicines includes the treatment naive patients on i st line therapy (n=20), transferred patients on ii nd line therapy (n=20), and patients with added tenofovir to basic therapy (n=6) -ii nd line therapy. their monthly cost per patient is presented on Table 4 .
Budget impact for the patients on the Ist line therapy (Ist scenario)
For the patients on the first line therapy (without the new medicines) the main budget dominance per patient is the medicines cost (Fig. 1) . the yearly cost of consultations and laboratory tests is extremely low and did not significantly affect the individual budget, although that every patient had at least 12 consultations and tests per year. the yearly cost per patient in the current state, which did not involve the use of the new biotechnology products varied between 3000 and 12000 euro. the results for the patients in the new state are similar, where again the cost of medicines is the main budget dominance but there are more evident discrepancies among the individual cost per patients on particular therapy in comparison with the current state (Fig. 2) . the difference of the individual budget impact per patient in the new state depends on the type of the patient-treatment naive (first part in Fig. 2) or one who switched to another therapy (second part in Fig. 2) . the budget cost of patients that are switched to new therapy is increasing. comparing the budget cost for patients in the current state and new state there is evident increase in the annual cost due to the introduction of the new medicines. For treatment of naive patients the cost varies from 8000 to 13000 euro, and for the switched-therapy patients it varies between 5000 and 13000 euro. thus, the addition of the new medicines let to the increase in the yearly budget per patient with 1000 to 5000 euro in comparison with the current state and depends on the other previous medicines left in the combination. the Budget impact cost calculated as the difference among the new state and current state is shown on Fig. 3 . the budget impact per patient in the new state is higher than in the current state but the whole yearly budget is lower due to lower number of patients in that state (Fig. 3) . When costs are calculated for all patients the difference is negative because the Bi cost of the new state is lower than the Bi cost of the current state. thus, patients in the new state did not add significant value to the current state therapy.
Budget impact for the patients on the IInd line therapy (IInd scenario) the second line therapy is usually started when adverse drug events or resistance against the first line therapy is observed. It requires obligatory inclusion of the new medicines depending on the clinical guidelines.
When the medication cost and yearly cost per patient including the ambulatory tests and consultations are compared it is again shown that the main budget dominance is the medicines cost for the current as well as for the new state (Fig.  4 and Fig. 5) .
the Bi cost of the new medicines is shown on Fig. 6 . the huge difference between the values is due to the fact that in the current state there are only two regimes while in the new state there are 15 therapeutic regimes in the ii nd line therapy and also there are more patients in the new state.
The first budget impact analysis for the HAART in Bulgaria at national level was done for tenofovir disoproxil fumarate and emtricitabine in 2008 year (6) . this analysis evaluates the budget impact of two newly registered for Bulgaria antiretroviral medicines for the treatment of hiV infectiontenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) soon after their introduction in the therapeutic practice in the country. Predictions were made that the budget impact will not At present TDF is included in 27 highly active antiretroviral combinations and FTC, in 7 combinations, as one of the combinations is the predicted one -TDF-FTC-EFV and darunavir in 2 combinations. We now found that not only the number of patients increased but also the number of therapeutic regimes.
the addition of the new medicines increases total budget more evidently for the patients on ist line therapy than for the patients on iind line therapy. this could be explained with the fact that the patients on first line therapy use well established medicines with lower prices. We also found that for the second line therapy for some of the patients the cost is decreasing and thus there are savings realised after the introduction of the new medicines.
it could be recommended for the treatment of naive patients that it is better to start the therapy with combinations including the new medicines due to the reported low resistance rate and lower toxicity in the clinical trials, and due to the further possible saving as shown in our analysis (17, 18) .
our results are based on the information from the biggest national hiV clinic that serves approximately two thirds of all hiV patients. if the other 3 clinics follow the same treatment patterns, the introduction of tenofovir disoproxil, emtricitabine and darunavir could lead to the higher saving for the health care budget.
A limitation in our study concerns the reliance on expert opinion. however, there is no other possible source of information and also the methodology allows inclusion of different sources of information.
comparison among our results with other international studies shows that in Bulgaria the main budget dominance is the medicines cost while in other countries the health services are more expensive (15) .
Conclusions
the budget impact of the new highly active antiretroviral therapy depends mainly on the new biotechnology medicines cost.
For the observed clinical centre (University Specialized hospital for intensive care in infectious and Parasite Diseases) the addition of the new highly active antiretroviral biotechnology medicines (tenofovir disoproxil, emtricitabine and darunavir) led to the decrease in the yearly budget cost for patients on iind line therapy.
